The effect of dexmedetomidine and clonidine on the inflammatory response in critical illness:a systematic review of animal and human studies by Flanders, Charles A et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The effect of dexmedetomidine and clonidine on the
inflammatory response in critical illness
Citation for published version:
Flanders, CA, Rocke, AS, Edwardson, SA, Baillie, JK & Walsh, TS 2019, 'The effect of dexmedetomidine
and clonidine on the inflammatory response in critical illness: a systematic review of animal and human
studies', Critical Care, vol. 23, no. 1, pp. 402. https://doi.org/10.1186/s13054-019-2690-4
Digital Object Identifier (DOI):
10.1186/s13054-019-2690-4
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Critical Care
Publisher Rights Statement:
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source,
provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons
Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made
available in this article, unless otherwise stated.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 11. May. 2020
RESEARCH Open Access
The effect of dexmedetomidine and
clonidine on the inflammatory response in
critical illness: a systematic review of
animal and human studies
Charles A. Flanders1† , Alistair S. Rocke1†, Stuart A. Edwardson2, J. Kenneth Baillie1 and Timothy S. Walsh1,2,3*
Abstract
Background: The α2 agonists, dexmedetomidine and clonidine, are used as sedative drugs during critical illness.
These drugs may have anti-inflammatory effects, which might be relevant to critical illness, but a systematic review
of published literature has not been published. We reviewed animal and human studies relevant to critical illness to
summarise the evidence for an anti-inflammatory effect from α2 agonists.
Methods: We searched PubMed, the Cochrane library, and Medline. Animal and human studies published in
English were included. Broad search terms were used: dexmedetomidine or clonidine, sepsis, and inflammation.
Reference lists were screened for additional publications. Titles and abstracts were screened independently by two
reviewers and full-text articles obtained for potentially eligible studies. Data extraction used a bespoke template
given study diversity, and quality assessment was qualitative.
Results: Study diversity meant meta-analysis was not feasible so descriptive synthesis was undertaken. We
identified 30 animal studies (caecal ligation/puncture (9), lipopolysaccharide (14), acute lung injury (5), and
ischaemia-reperfusion syndrome (5)), and 9 human studies. Most animal (26 dexmedetomidine, 4 clonidine) and all
human studies used dexmedetomidine. In animal studies, α2 agonists reduced serum and/or tissue TNFα (20
studies), IL-6 (17 studies), IL-1β (7 studies), NFκB (6 studies), TLR4 (6 studies), and a range of other mediators. Timing
and doses varied widely, but in many cases were not directly relevant to human sedation use. In human studies,
dexmedetomidine reduced CRP (4 studies), TNFα (5 studies), IL-6 (6 studies), IL-1β (3 studies), and altered several
other mediators. Most studies were small and low quality. No studies related effects to clinical outcomes.
Conclusion: Evidence supports potential anti-inflammatory effects from α2 agonists, but the relevance to clinically
important outcomes is uncertain. Further work should explore whether dose relationships with inflammation and
clinical outcomes are present which might be separate from sedation-mediated effects.
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Background
The α2 agonists dexmedetomidine and clonidine are widely
used as sedative drugs during critical illness, acting by dose-
dependent decrease in activity of noradrenergic neurons in
the brain stem via post-synaptic receptor-mediated inhib-
ition [1]. This increases gamma-aminobutyric acid (GABA)
neurone activity, which mediates central sedative effects.
Dexmedetomidine, a highly selective α2 agonist (α2:α1 re-
ceptor selectivity ratio 1620:1), is licenced for intensive care
unit (ICU) sedation and systematic reviews suggest it de-
creases duration of mechanical ventilation and ICU stay
compared with propofol and/or benzodiazepines [2–4]. Ef-
fects on delirium are less certain [2, 4], but recent trials sug-
gest dexmedetomidine can decrease delirium in selected
populations, even when used in low doses [5]. Clonidine
has substantially lower α2:α1 selectivity (220:1), is
unlicensed for ICU sedation, but is also widely used in
some countries. Despite this popularity, evidence for clin-
ical effectiveness is very limited and of poor quality [6].
α2 agonists decrease central sympathetic nerve activity,
which might affect inflammation and immune function
either directly via cell surface receptors or indirectly by
altering sympathetic/parasympathetic balance [7–9].
Although α2 agonists cause bradycardia, they may
paradoxically increase cardiovascular stability in shock
[10–12]. A post hoc trial analysis [13] and prospective
clinical trial [14] suggest trends towards improved
survival in sepsis when dexmedetomidine is used for
sedation but remains unproven and was not observed in
the recent large SPICE III randomised trial [15].
If α2 agonists have effects via mechanisms other than
sedation, these could be important for clinical practice.
Any anti-inflammatory effects could plausibly explain
putative effects on delirium, shock, and other organ dys-
function and might explain why low doses of dexmede-
tomidine decrease delirium in perioperative patients
[16]. Current evidence for anti-inflammatory effects
from α2 agonists in critical illness has not previously
been summarised. We therefore undertook a systematic
review of relevant animal and human studies of critical
illness to summarise current evidence.
Methods
Inclusion criteria
Eligible studies were animal or human studies under-
taken in the context of sepsis, inflammation, or both.
We limited studies to those that included dexmedetomi-
dine or clonidine. All included studies required a bio-
logical measure of the inflammatory response as an
outcome.
Search
We searched PubMed, the Cochrane library, and Med-
line in accordance with the PRISMA guidelines; the
PRISMA checklist is available as an Additional file 1.
The final search was done on May 14, 2019. Search
terms used were broad: dexmedetomidine, sepsis and in-
flammation; and clonidine, sepsis and inflammation. We
had no date limits but included only studies published in
English. Reference lists were screened for additional
publications. After removing duplicates, titles and ab-
stracts were screened independently by two reviewers
(CAF and ASR) and full-text articles obtained wherever
possible for all potentially eligible studies. Disagreements
were resolved between the two reviewers, with reference
to the senior author (TSW). Full-text articles were re-
trieved from the National Health Service, Athens, Know-
ledge Network, University of Edinburgh, and the British
Library. Where a full-text article was unavailable and
there was insufficient information in the abstract to de-
termine eligibility, it was excluded.
For eligible studies, data were extracted into a table
that summarised: type of study (animal, human), popula-
tion, interventions used and comparators, outcomes, key
summary findings, and any relevant additional com-
ments or findings (see Additional files 2, 3, 4 and 5).
We grouped studies as follows:
Animal studies
Sepsis models (caecal ligation and puncture (CLP), and
lipopolysaccharide (LPS)), acute lung injury models
(ALI), and ischaemia/reperfusion injury (IRI) models.
Human studies
Any human study involving perioperative and/or critic-
ally ill patients fulfilling inclusion criteria.
As the type and range of studies varied widely and
were mostly animal models, we did not undertake formal
quality assessment using an existing tool. Instead, we
documented potentially important limitations qualita-
tively for each study. Evidence synthesis was descriptive,
because data were not suitable for meta-analysis.
Results
The search identified 188 records; manual reference
searching identified an additional 21 records. After re-
moving duplicates 140 study abstracts were screened,
and 95 selected for full text analysis. After full text re-
view, 53 articles did not meet inclusion criteria and 42
articles were included in the review. The PRISMA flow-
chart is shown in Fig. 1. We identified 33 animal studies
(9 CLP, 14 LPS, 5 ALI, 5 IRI) and 9 human studies.
Animal studies
The key inflammatory molecules tested are described in
Table 1 with a summary of all animal studies in Add-
itional file 2 and a detailed description in
Additional file 3.
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Caecal ligation and puncture (CLP)
The nine CLP models were undertaken in rats [17,
21–23, 34, 41, 42] and mice [36, 37]. Seven studies
used dexmedetomidine [17, 22, 23, 34, 36, 37, 41,
42] and one clonidine [21]. Study size ranged from
21 to 210 animals with a range of control group de-
signs. Routes of administration were intraperitoneal
[22, 36, 41, 42] and intravenous [17, 21, 23, 34, 37]
as well as bolus [21–23, 36, 37, 41, 42] versus infu-
sion [17, 34]. Study design included pre-only groups
[34, 42], pre/post groups [21, 36], and post-only [17,
22, 23, 37, 41] designs. Three studies included α2
agonist blockade groups [17, 23, 42]. A range of dex-
medetomidine doses was used but in most studies
was high compared to human sedative doses. Dur-
ation of experiments varied widely (6 h to 7 days),
but most were less than 24 h with widely varying
sampling schedules.
Hofer et al. found both high dose intraperitoneal cloni-
dine (5 μg/kg) and dexmedetomidine (40 μg/kg) de-
creased NFκB and pro-inflammatory cytokines (TNFα,
IL-1β, IL-6) and improved survival [21], with effects
most marked with pre-CLP administration. Qiao et al.
found dexmedetomidine (5 μg/kg/h infusion) reduced
Tumour necrosis factor alpha (TNFα), Interleukin-6 (IL-
6), and caspase-3 but found similar effects from midazo-
lam [34]. Wu et al. found higher doses of intraperitoneal
dexmedetomidine (range 10–20 μg/kg) reduced inflam-
matory response within the lungs (bronchoalveolar lav-
age [BAL] TNFα, IL-6; lung tissue Toll-like receptor 4
(TLR4), Myeloid differentiation primary response 88
(MyD88), and NFκB) and improved survival [22]. Xu
et al. found intravenous dexmedetomidine bolus (40 μg/
kg) decreased TNFα and IL-6, with greatest effects after
24 h, and improved survival. Effects were greatest with
pre-CLP dexmedetomidine administration [36]. Koca
Fig. 1 Systematic review PRISMA flowchart
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Table 1 Inflammatory molecules tested in animal studies
Animal studies
Inflammatory molecule Alteration with α2 agonist Location Citation
Myeloperoxidase Decreased Lung tissue
Bronchoalveolar lavage fluid
Epigastric skin tissue flap
Chen et al. [17]
Jiang et al. [18]
Uysal et al. [19]
Nuclear factor Kappa B Decreased Lung tissue
Bronchoalveolar lavage fluid
Myocardial tissue
Chen et al. [17]
Kong et al. [20]
Hofer et al. [21]
Wu et al. [22]
Zhang et al. [23]
Shen et al. [24]
Nitric Oxide/inducible nitric oxide synthase mRNA Decreased Lung tissue
Serum
Epigastric skin tissue flap
Chen et al. [17]
Yang et al. [25]
Yang et al. [26]
Sugita et al. [27]
Uysal et al. [19]
Tumour Necrosis Factor- α Decreased Lung tissue
Bronchoalveolar lavage fluid
Serum
Myocardial tissue
Jiang et al. [18]
Loftus et al. [28]
Yang et al. [26]
Chen et al. [3]
Kang et al. [29]
Kong et al. [20]
Tan et al. [30]
Taniguchi et al. [31]
Taniguchi et al. [32]
Xiang et al. [33]
Chen et al. [17]
Hofer et al. [21]
Qiao et al. [34]
Wu et al. [22]
Feng et al. [35]
Xu et al. [36]
Zhang et al. [23]
Shen et al. [24]
Sugita et al. [27]
Zhang et al. [4]
Interleukin-6 Decreased Lung tissue
Bronchoalveolar lavage fluid
Serum
Myocardial tissue
Jiang et al. [18]
Yang et al. [25]
Chen et al. [17]
Kong et al. [20]
Tan et al. [30]
Feng et al. [35]
Taniguchi et al. [31]
Taniguchi et al.
Xiang et al. [32]
Chen et al. [3]
Hofer et al. [21]
Kang et al. [29]
Qiao et al. [34]
Zhang et al. [37]
Wu et al. [22]
Xu et al. [36]
Zhang et al. [23]
Shen et al. [24]
Sugita et al. [27]
Zhang et al. [4]
Toll-like Receptor 4 Decreased Lung tissue
Intestinal tissue
Myocardial tissue
Jiang et al. [18]
Chen et al. [17]
Wu et al. [22]
Zhang et al. [23]
Shen et al. [24]
Zhang et al. [4]
Myeloid Differentiation Primary Response 88 (MyD88) Decreased Lung tissue
Myocardial tissue
Jiang et al. [18]
Wu et al. [22]
Zhang et al. [23]
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et al. found intraperitoneal dexmedetomidine (50 μg/kg
post-CLP) decreased acute kidney injury (histology, cre-
atinine, and Neutrophil gelatinase-associated lipocalin
(NGAL)) and inflammatory markers (Cytokeratin 18
(CK18); M30) 6 h post-injury [41]. Zhang et al. found
intravenous dexmedetomidine (5 or 10 μg/kg bolus post-
CLP) attenuated all measured inflammatory markers
(TNFα, IL-6, TLR4, MyD88, and NFκB) 6 h post-injury,
but effects were not reduced by yohimbine [23]. Chen
et al. found intravenous dexmedetomidine (5 μg/kg over
1 h) attenuated all inflammatory markers (TNFα,
Interleukin-1β (IL-1β), IL-6, TLR4) and lactate produc-
tion when delivered 30min post-CLP, and improved
survival; these effects were partially prevented by yohim-
bine [17]. Zhang et al. found intravenous dexmedetomi-
dine at various doses (0.1, 0.3, 0.5 mg/kg) given 30 min
post-CLP improved serum IL-6 and IL-1β [37]. Finally,
Zhang et al. found dexmedetomidine (10 μg/kg) im-
proved survival and histological lung injury scores
(including tissue caveolin-1 expression), with effects par-
tially reversed by the antagonist APZ [43].
Lipopolysaccharide (LPS) administration
The 14 LPS models were undertaken in rats [30–33, 35,
44–47], mice [20, 29, 38, 48], and hamsters [40]. Thir-
teen studies used dexmedetomidine [20, 22, 29–33, 35,
40, 44–47] and one clonidine [38]. Study size ranged
from 40 to 104 animals. Design varied widely and in-
cluded pre-LPS only [20, 29, 30, 32, 33, 35, 38], post-
LPS only [31, 40, 44–46, 48], and at initiation of LPS
[47]. LPS was administered intravenously in all studies.
Five studies [29, 30, 35, 38, 44] included comparison
with α2 antagonist treatment. Doses (2.5 to 50 μg/kg)
and duration of experiments (range 3 to 20 h) varied
widely but most were short duration.
Taniguchi et al. found intravenous dexmedetomidine
5 μg/kg/h post-LPS decreased TNFα and IL-6, improved
survival, and decreased lung neutrophil infiltration over
Table 1 Inflammatory molecules tested in animal studies (Continued)
Animal studies
Inflammatory molecule Alteration with α2 agonist Location Citation
Zhang et al. [4]
Interleukin-10 Decreased Serum Szelenyi et al. [38]
Vascular endothelial growth factor Increased Lung tissue Loftus et al. [28]
Vascular endothelial growth factor receptors 1 and 2 Increased Lung tissue Loftus et al. [28]
Interleukin-1b Decreased Lung tissue
Serum
Myocardial tissue
Yang et al. [25]
Yang et al. [26]
Kong et al. [20]
Zhang et al. [37]
Xiang et al. [33]
Feng et al. [35]
Chen et al. [17]
Hofer et al. [21]
Α-7 nicotinic acetylcholine receptor Increased Myocardial tissue Kong et al. [20]
Organic hyperoxides and superoxide radicals Decreased Lung tissue
Hepatic tissue
Ileal tissue
Chen et al. [17]
Filos et al. [39]
High Mobility Group Box 1 (HMGB1) Decreased Lung tissue
Renal tissue
Myocardial tissue
Serum
Loftus et al. [28]
Tan et al. [30]
Xu et al. [36]
Zhang et al. [4]
Kidney Injury Molecule 1(KIM1) Decreased Renal tissue Tan et al. [30]
B-Actin Decreased Serum Yang et al. [25]
Cyclo-oxygenase 2 (COX-2) Decreased Serum Yang et al. [25]
Yang et al. [26]
Prostaglandin E2 (PGE2) Decreased Serum Yang et al. [26]
Macrophage inflammatory protein 2 (MIP2) Decreased Serum Yang et al. [26]
Lactate Decreased Serum Chen et al. [17]
Miranda et al. [40]
Chen et al. [3]
Malondialdehyde (MDA) Decreased Renal tissue
Epigastric skin tissue flap
Chen et al. [3]
Koca et al. [41]
Uysal et al. [19]
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8 h [31]. A further study described dose-dependent re-
duction (dexmedetomidine 2.5 to 10 μg/kg/h) in TNFα
and IL-6 over 5 h when started pre-LPS administration;
effects were absent with lowest doses, and post-LPS
administration had less marked effects [32]. Sezer et al.
found intravenous dexmedetomidine 5 μg/kg/h
decreased histological markers of inflammation 8 h post-
LPS [45]. Shi et al. administered three boluses of dexme-
detomidine (0.5, 1.5, and 4.5 μg/kg) and found lung
TNFα, IL-6, IL-1β, TLR4, NFκB, and lung wet/dry ratios
were all decreased with the two higher (but not the low-
est) dexmedetomidine doses [46]. Kong et al. found dex-
medetomidine administered as a 10mg/kg bolus 1 h
prior to LPS reduced myocardial apoptosis, NFκB, IL-6,
and IL-1β and was attenuated by α-bungarotoxin (ABT),
an antagonist at the α-7 nicotinic acetylcholine receptor
[20]. Szelenyi et al. found intraperitoneal clonidine (5
mg/kg), administered 30 min prior to LPS, significantly
reduced Interleukin-10 (IL-10) and was reversed when
α2 antagonists (CH- 38083, WB04101, Prazosin) were
administered [38]. Yeh et al. found intravenous dexme-
detomidine (5 μg/kg/h) administered concurrently with
LPS showed no harmful effect on cardiovascular param-
eters and reduced small bowel markers of endothelial
dysfunction [47]. Wu et al. found dexmedetomidine 5
and 50 μg/kg/h infusion for 8 h from LPS administration
attenuated T and B cell production, reduced macro-
phage phagocytosis at both doses, and increased NK cell
activity at the high dexmedetomidine dose [48]. Xiang
et al. administered dexmedetomidine 40 μg/kg as a bolus
pre-LPS and found attenuation of TNFα, IL-6, and IL-1β
and improved survival; effects were reversed by adminis-
tration of the α2 antagonist ABT [33]. Chen et al. found
intravenous dexmedetomidine 5 μg/kg/h attenuated a
range of blood and liver inflammatory/injury markers,
which was attenuated by yohimbine [44]. Miranda et al.
used a skinfold chamber technique to study microcircu-
lation in a hamster LPS model of dexmedetomidine
5 μg/kg/h 1 h post-LPS, finding no difference in vasodila-
tation, but a reduction in leukocyte rolling following
dexmedetomidine [40]. Feng et al. administered dex-
medetomidine at 25 μg/kg as a bolus pre-LPS and
found attenuation of TNFα, IL-6, IL-8, and IL-1β.
This effect was reversed when administered with ATZ
[35]. Kang et al. found that dexmedetomidine admin-
istered at 40 μg/kg attenuated serum TNFα and IL-6
when given 1-h pre-LPS induced acute kidney injury.
This effect was reversed when administered with the
α2 antagonist ABT [29]. Finally, Tan et al. observed a
decrease in TNFα, IL-6, Interleukin-8 (IL-8), and in
renal High mobility group protein B1 (HMGB1) ex-
pression following pre-LPS dexmedetomidine 10 μg/kg
administration, which was attenuated by concurrent
yohimbine administration [30].
Acute lung injury models
Five studies were undertaken in rats [18, 25, 26, 28] and
dogs [49]. Four used dexmedetomidine [18, 25, 26, 49]
and one clonidine [28]. Study size ranged from 30 to 84
animals. The ALI model was ventilator-induced lung in-
jury (VILI) [25, 26, 49], ischaemia [18], and trauma [28].
Two studies [18, 25] included α2 agonist blockade
groups. The dose varied widely 0.5 to 5 μg/kg/h dexme-
detomidine and duration of experiments from 4 h to 7
days.
Yang et al. used a rat VILI model (10 versus 20mL/kg)
and compared effects from 0.5, 2.5, and 5 μg/kg dexmede-
tomidine. Lung histology studies and expression of TNFα,
IL-1β, IL-6, macrophage inflammatory protein 2 (MIP-2),
Nitric Oxide (NO), Prostaglandin E2 (PGE2), Nitric oxide
synthase (iNOS), Cyclooxygenase 2 (COX2), and β-actin
showed only the 5 μg/kg dose attenuated inflammation;
the effect was attenuated by yohimbine [25]. In a further
study, this group found intravenous dexmedetomidine at
lower dose (0.5 μg/kg/h) reduced VILI in an LPS-plus-
VILI model, based on histology and pro-inflammatory
markers [26]. Chen et al. induced VILI in dogs (20mL/
kg), studied three intravenous dexmedetomidine doses
from intubation (0.5, 1.0, and 2.0 μg/kg/h), and examined
lung injury at 4 h. They found dose-dependent reduction
in lung TNFα, iNOS, NFκB, and BAL Myeloperoxidase
(MPO) and Polymorphonuclear neutrophils (PMN), with
increasing dexmedetomidine dose [49]. Jiang et al. studied
pre-injury dexmedetomidine (2.5 and 5 μg/kg/h) effects in
an ischaemia (hilar occlusion) model of ALI in rats, find-
ing dexmedetomidine reduced lung injury scores and in-
flammatory markers (MPO, TNFα, IL-6, TLR4, MyD88,
Phospho-JNK, and Phospho-ERK); yohimbine partially re-
versed effects on some injury markers [18]. Finally, Loftus
et al. used a complex trauma model including haemor-
rhage, lung contusion, and stress over 7 days to explore
the effects of clonidine (10 μg/kg) on lung injury, finding
high doses of clonidine increased vascular endothelial
growth factor (VEGF) and its receptor expression in the
lungs [28].
Ischaemia-reperfusion injury (IRI) models
The five studies were all in rats, four dexmedetomidine
[19, 24, 27, 43] and one clonidine [39]. Study size ranged
from 30 to 80 animals. Two studies [24, 43] included α2
agonist blockade groups. Doses varied widely 0.5 to
5 μg/kg/h dexmedetomidine, as did duration of experi-
ments (4 h to 7 days).
Filos et al. used a haemorrhage model and studied the
effects of clonidine pre-treatment (150 μg/kg subcutane-
ously) on circulating endotoxin and tissue superoxide
radicals, finding both were reduced [39]. Uysal et al.
used a femoral artery/vein clamp model to study effects
of dexmedetomidine 10 and 30 μg/kg on an epigastric
Flanders et al. Critical Care          (2019) 23:402 Page 6 of 11
island skin flap 12 h and 7 days post-IRI finding both
doses reduced tissue NO, MDA, and MPO at both time
points, and reduced flap necrosis area [19]. Shen et al.
used a superior mesenteric artery occlusion model to
study effects of dexmedetomidine 2.5 and 5 μg/kg/h in-
fusion pre-IRI on lung injury, finding dose-dependent
reductions in lung TLR4 and MyD88 (but not phosphoi-
nositide 3-kinase (Pi3k) or Protein kinase B (AKT)) and
improved lung histology and wet/dry weight ratio, with
effects unaltered by yohimbine [24]. Sugita et al. studied
effects of dexmedetomidine 10 and 20 μg/kg/h from the
time of reperfusion on circulating TNFα, IL-6, IL-6, and
NOS, finding attenuation of IL-6 and iNOS, but not
TNFα, Endothelial derived nitric oxide (eNOS), or Neur-
onal nitric oxide (nNOS) 6 h post-IRI [27]. Finally,
Zhang et al. studied the effects of dexmedetomidine in-
fusion on myocardial injury in a coronary occlusion
model, finding a reduction in infarct size and all mea-
sures of myocardial inflammation studied; this effect was
attenuated by yohimbine [43].
Human studies
We identified nine randomised controlled studies in
humans. The populations were elective one-lung ventila-
tion [50], laparoscopic cholecystectomy [51, 52], abdom-
inal surgery [53, 54], spinal fusion surgery [55], cardiac
surgery [56], and sepsis [14, 57]. All studies used dexme-
detomidine; none used clonidine. Comparator treatments
varied, comprising a control/placebo [50–52, 55, 56], pro-
pofol [14, 53, 54], and midazolam [57]. Size ranged from
20 to 201 patients; eight studies had a total size < 50 pa-
tients. Dexmedetomidine timing and dose varied: single
bolus [50], in seven [51–57] as a bolus (range 0.5 to
2.5 μg/kg) followed by an infusion (range 0.5 to 2.5 μg/kg/
h), and titration to a sedation target [14].
C Reactive Protein (CRP) was measured in four
studies [14, 51, 55, 56] and was decreased in all stud-
ies compared to the comparator. TNFα was measured
in five studies [50, 51, 53, 55, 57] and was reduced in
all studies compared to the comparator. IL-6 was
measured in six studies [51, 53–57]; dexmedetomidine
decreased IL-6 in four studies [53, 55–57], but in two
[51, 54] no difference was detected. IL-1β was mea-
sured in three studies [51, 53, 57] and was decreased
in all studies. Other findings included a reduction in
IL-10 [51], a transient attenuation of NFκB [56], an
increase in the interferon/IL-4ratio [52], a decrease in
CD42a/CD14 ratio and an increase in Human
leukocyte antigen-DR isotype (HLA-DR)/CD14 ratio
with dexmedetomidine [55]. The key inflammatory
molecules tested are described in Table 2 with a sum-
mary of each study in Additional file 4 and a detailed
description in Additional file 5.
Discussion
We found both animal and human studies supported anti-
inflammatory effects from the α2 agonists used in treat-
ment of critically ill humans, namely dexmedetomidine
and clonidine. However, only four animal and no human
evaluated the effects of clonidine. There was wide variabil-
ity in animal study design, but overall results were consist-
ent with a reduction in markers of inflammation and
organ injury. Anti-inflammatory effects were also observed
in most human studies [14, 50, 51, 53, 55–57].
Animal studies were heterogeneous in design in relation
to the stimulus (LPS, CLP, IRI, and VILI), route of admin-
istration and timing of α2 agonist, and dose regimen used.
There was variation in the biological/pathological marker
of inflammation used, but effects on pro-inflammatory cy-
tokines were broadly consistent across studies. Studies
using antagonists [4, 18, 20, 25, 29, 30, 33, 35, 38, 44]
mostly suggested attenuation or elimination of effects,
supporting a receptor-mediated mechanism, but this was
not universal. The relevance of the animal studies to hu-
man disease is uncertain, especially because doses were
mostly significantly higher than licenced for human use.
No study measured plasma drug concentrations. Although
the relevance to established critical illness of pre-insult
administration is uncertain, this might be relevant to peri-
operative administration during major surgery. The co-
administration of drugs such as ketamine in some studies
[21, 26] might also interact with α2 agonist pathways, lim-
iting relevance to human disease. Few studies measured
concurrent cardiovascular responses [21, 27, 31, 32, 47],
which are potentially important side effects in humans,
and almost all studies were undertaken in small animals,
which may not be relevant models to human inflamma-
tory disease. The consistency of reported effects across
studies supports potentially relevant modulation of in-
flammation and/or immune responses. However, we can-
not exclude an influence from publication bias.
Of the nine human studies, only two were undertaken
in critically ill patients with sepsis or other clear inflam-
matory conditions [14, 57]; the remainder included
elective surgical populations [20, 50, 52–56]. Most stud-
ies performed serum cytokine assays until around 48 h
post-operatively and observed reductions compared with
control patients in the immediate post-operative period.
The main study limitations were small sample size and
the uncertain relevance of inflammatory mediator con-
centrations to clinical outcomes. All of the 9 human
studies used dexmedetomidine. The largest study was
undertaken in mechanically ventilated septic patients
and had non-significantly different clinical primary out-
comes (mortality and ventilation-free days). Dexmedeto-
midine doses were smaller than those widely used for
clinical sedation (0.1–0.7 μg/kg/h), but despite this the
observed reduction in CRP concentrations is consistent
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with an anti-inflammatory effect. This study did not
measure pro- or anti-inflammatory pathways [14]. The
size and quality of the human studies was generally low,
populations were heterogeneous, and most populations
did not have severe illness. Anti-inflammatory effects
were observed for potentially relevant inflammatory me-
diators in all studies, but none linked modulation of in-
flammation to clinical outcomes.
This is the first systematic review of the anti-
inflammatory effects of dexmedetomidine and clonidine
that includes both human and animal studies. We in-
cluded studies covering a wide range of inflammatory in-
sults including animal sepsis, ARDS and ischemia
models, human critical illness, and major surgical inter-
ventions. In animal studies, we also specifically described
the dose of α2 agonist used and timing of administration
to highlight relevance to human disease. The only other
published systematic review described anti-inflammatory
effects of perioperative dexmedetomidine as an adjunct
to general anaesthesia and found significant reductions
in perioperative IL-6, IL-8, TNFα concentrations, and
post-operative IL-10. It also observed wide variation in
the surgery studied and high statistical heterogeneity of
effects between studies. However, the relevance to clin-
ical outcomes was not included and only dexmedetomi-
dine administered pre-operatively was reviewed [8]. Our
review summarised the available animal data and also
highlights the limited evidence for clonidine. Taken to-
gether, these data support a possible anti-inflammatory
effect from α2 agonists but are inconclusive about the
clinical importance of this finding.
There are several suggested mechanisms for an anti-
inflammatory/immune regulatory effect from α2
agonists. These include modulation of macrophage/
monocyte function through α2-receptor-mediated inhib-
ition of apoptosis, central and peripheral α2-receptor
agonist-mediated effects, direct or indirect central sym-
patholytic effects, stimulation of cholinergic anti-
inflammatory pathways, reduction in anxiety and stress,
and indirect effects via anti-nociceptive and/or sedative
effects. The studies included in our review do not enable
the exact mechanisms to be conclusively elucidated, but
Table 2 Inflammatory molecules tested in human studies
Human studies
Inflammatory molecule Alteration with α2 agonist Location Citation
Interferon Gamma Increased Serum Kim et al. [52]
Tumour Necrosis Factor- α Decreased Serum Gao et al. [50]
Kang et al. [51]
Memis et al. [57]
Tasdogan et al. [53]
Zhou et al. [55]
Superoxide Dismutase Decreased Serum Gao et al. [50]
Malondialdehyde Decreased Serum Gao et al. [50]
Heme-oxygenase 1 Decreased Lung tissue Gao et al. [50]
White Cell count Decreased Serum Kang et al. [51]
Zhou et al. [55]
Interleukin-1b Decreased Serum Kang et al. [51]
Memis et al. [57]
Tasdogan et al. [53]
Interleukin-6 Decreased Serum Kang et al. [18]
Memis et al. [57]
Tasdogan et al. [53]
Ueki et al. [56]
Venn et al. [54]
Zhou et al. [55]
Interleukin-10 Decreased Serum Kang et al. [51]
Zhou et al. [55]
C Reactive Protein Decreased Serum Kang et al. [51]
Kawazoe et al. [14]
Ueki et al. [56]
Zhou et al. [55]
Procalcitonin No statistically significant change Serum Kawazoe et al. [14]
Prealbumin No statistically significant change Serum Kawazoe et al. [14]
Nuclear Factor Kappa B Decrease Serum Ueki et al. [56]
High Mobility Group Box 1 (HMGB1) Decrease Serum Ueki et al. [56]
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those that included an antagonist [4, 18, 20, 25, 29, 30,
33, 35, 38, 44] mostly showed attenuation of α2 receptor
agonist-mediated anti-inflammatory/immune regulatory
effects suggesting a receptor-mediated effect is an im-
portant mechanism. This, however, was not a universal
finding.
Whether anti-inflammatory effects are on a causative
pathway to improved clinical outcomes in human critical
illness is unproven. In the recent SPICE trial, which
compared early dexmedetomidine based sedation with
usual care (mostly propofol and/or midazolam) no over-
all mortality benefit was found and there was also no
mortality benefit in a large sepsis sub-group (in whom
an anti-inflammatory benefit may be most biological
plausible) [15]. However, there were beneficial effects on
both ventilation duration and delirium, and in a sub-
group analysis the authors observed differences in the ef-
fect on mortality between younger (greater mortality
with dexmedetomidine) and older (lower mortality with
dexmedetomidine) patients for which the significance is
uncertain. The mechanism of differential age-related
effects of these agents is unexplained, but non-sedation
related actions potentially, including immune/inflamma-
tory modulation, might contribute. Further human stud-
ies are needed to explore whether the anti-inflammatory
properties of α2-agonists are clinically important and
whether differences between dexmedetomidine and clo-
nidine might influence their modulation of clinical
outcomes.
Our review has several limitations. Firstly, we used
broad search terms to try and capture a wide range of
studies, but we may have missed potentially relevant
papers. Second, we cannot exclude publication bias espe-
cially for animal studies. Third, quantitative meta-
analysis was not undertaken, because we did not
consider this plausible or relevant for the identified lit-
erature; our data synthesis was therefore descriptive.
Conclusion
In conclusion, although the quality of animal and human
studies is low, we have shown that α2 agonist drugs may
potentially modify inflammatory and immune pathways
in acute inflammatory conditions. Further work is re-
quired, especially in critically unwell humans, to explore
mechanisms of action and whether these translate into
improved patient outcomes.
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